In the US, Bevacizumab (bevacizumab systemic) is a member of the drug class VEGF/VEGFR inhibitors and is used to treat Breast Cancer, Breast Cancer - Metastatic, Cervical Cancer, Colorectal Cancer, Fallopian Tube Cancer, Glioblastoma Multiforme, Macular Degeneration, Malignant Glioma, Neurofibromatosis, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Peritoneal Cancer, Renal Cell Carcinoma and Solid Tumors.
ATC (Anatomical Therapeutic Chemical Classification)
CAS registry number (Chemical Abstracts Service)
Vascular endothelial growth factor (VEGF) antagonist
Immunoglobulin G1 (human-mouse monoclonal rhuMAb-VEGF gamma-chain anti-human vascular endothelial growth factor), disulfide with human-mouse monoclonal rhuMab-VEGF light chain, dimer (WHO )
- Bevacizumabum (Latin)
- Bevacizumab (German)
- Bévacizumab (French)
- Bevacizumab (Spanish)
- Bevacizumab (OS: USAN)
- Bevacizumab (Genetical Recombination) (OS: JAN)
- anti-VEGF Mab (IS)
- Anti-VEGF monoclonal antibody (IS)
- rhuMAb-VEGF (IS)
- UNII-2S9ZZM9Q9V (IS)
- VEGF light chain, dimer (IS: WHO)
Chugai Pharmaceutical, Japan; euro rx Arzneimittel GmbH, Austria; F. Hoffmann-La Roche, Macedonia; F. Hoffmann-La Roche LTD, Serbia; Genentech, Georgia; Genentech, United States; Haemato Pharm, Austria; Hoffmann-La Roche, Bosnia & Herzegowina; Hoffmann-La Roche Ltd, Latvia; Inopha, Austria; Productos Roche, Chile; Roche, Armenia; Roche, Argentina; Roche, Australia; Roche, Belgium; Roche, Brazil; Roche, Canada; Roche, China; Roche, Colombia; Roche, Cyprus; Roche, Czech Republic; Roche, Germany; Roche, Denmark; Roche, Ecuador; Roche, Egypt; Roche, Spain; Roche, Finland; Roche, France; Roche, Greece; Roche, Croatia (Hrvatska); Roche, Hungary; Roche, Indonesia; Roche, Ireland; Roche, Israel; Roche, Iceland; Roche, Italy; Roche, Lebanon; Roche, Lithuania; Roche, Moldova; Roche, Myanmar; Roche, Mexico; Roche, Norway; Roche, New Zealand; Roche, Oman; Roche, Philippines; Roche, Poland; Roche, Romania; Roche, Serbia; Roche, Sweden; Roche, Thailand; Roche, Tunisia; Roche, Taiwan; Roche, Uruguay; Roche, Vietnam; Roche, South Africa; Roche Products, United Kingdom; Roche Registration, Austria
- Avastin Roche
Roche, Hong Kong
|JAN||Japanese Accepted Name|
|Rec.INN||Recommended International Nonproprietary Name (World Health Organization)|
|USAN||United States Adopted Name|
|WHO||World Health Organization|
Further information on drug naming conventions: International Nonproprietary Names.
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.